Forward Looking Statements

This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, whether the acquisition of ModeX, including the expansion of the executive management team, will positively impact the Company, whether ModeX will receive regulatory approval for products in development and be able to successfully commercialize such products, whether expectations after completion of the merger will be met, including the viability of the technology the benefits of and market for NGENLA and Rayaldee, the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, whether our products will launch in all the territories in which they have been approved for sale, our product development efforts and the expected benefits of our products, whether our products in development will be commercialized, whether the relationships and collaborations with our business partners will be successful, whether our business partners will be able to commercialize our products and successfully utilize our technologies, whether we will be able to successfully grow operations in our diagnostics business post-Covid, our ability to successfully expand our European and Latin American divisions, our ability to market and sell any of our products in development, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Diversified Diagnostic and Pharmaceutical Platforms in Growing Healthcare Landscape

Diagnostics

- One of the largest laboratories in the U.S., with a leading position in Women’s Health, Oncology, Urology and Strategic Ventures
- Post-Covid transition to core and specialty diagnostics focus

The 4Kscore® Test
- An FDA approved blood test for assessing the probability of aggressive prostate cancer

Pharmaceuticals

- Biotech company developing multi-specific immune therapies for cancer and infectious diseases acquired May 2022
- NGENLA™ (Somatrogon) launched by our global commercial partner, Pfizer, in several major markets, including Germany, Japan, Canada and Australia
- Rayaldee launched in Q1 2022 by our commercial partner, Vifor Fresenius, in several countries in Europe
- Latin American and European Pharmaceutical division
  - Continued growth
2022: A Transformational Year for OPKO

• Post-Covid Transition of Diagnostics Business back to Core and Specialty Diagnostics
  • Aggressive cost reductions in line with reduced COVID testing demand
  • Focus on expansion in Oncology, Women’s Health, Urology and Large Health Care Systems

• Continuing Performance of In-line Pharmaceutical Business
  • Latin America and Europe pharmaceutical division continuing expansion
  • Rayaldee for CKD 3-4 launched in Europe by partner Vifor
  • Long Acting Growth Hormone approved in ex-U.S. markets with early commercial launch by partner Pfizer. In the U.S., FDA review ongoing

• Transformational Acquisition of Leading Edge Biotech (ModeX Therapeutics) in Multispecific therapies for Oncology, Immunology and Infectious diseases (May 2022)
EVOLUTION OF THE DIAGNOSTICS DIVISION
### BioReference Overview

<table>
<thead>
<tr>
<th>Feature</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>One of the largest full services laboratories in the U.S.</td>
<td>&gt;80% payer coverage nationally</td>
</tr>
<tr>
<td>Serving all 50 States with labs in New Jersey, Texas, Florida and California, including CLIA certified labs in New York and Ohio</td>
<td>Specialty expertise in oncology, women’s health and urology</td>
</tr>
<tr>
<td>40-year history, with a menu of &gt;3,000 tests</td>
<td>3,300 employees serving ~10 million patients annually</td>
</tr>
</tbody>
</table>

**Driven by Two Complementary Sets of Attributes**

- **Deep expertise across the Core Commercial Lab Business,** operating high throughput facilities and specialty labs
- **A focus on high growth, high margin specialty diagnostics Oncology, Women’s health, Urology and strategic ventures**
BioReference’s Core Business Operates in a Large Market, with a Focus on High Growth Areas

Market Sizing

($ in billions)

- **Specialty Labs**: $13
- **Hospital Services**: $45
- **Outpatient & Independent Labs**: $36
- **Physician Office Labs**: $10

**Total US Lab Test Market (2019)**: $104bn

2-3% CAGR for total markets

Key Focus Areas for BioReference

- **Oncology**: >10%
- **Women’s Health**: >10%
- **Urology**: >10%
- **Ventures**: >15%

EVOLUTION OF THE PHARMACEUTICAL DIVISION
Vifor has received marketing authorizations for RAYALDEE in 11 European countries and has already initiated the commercial launch in Germany and Switzerland

- The first launch of RAYALDEE outside the U.S.
- Once daily oral formulation of the prohormone 25D₃* addresses significant unmet need
- Only product approved by FDA to treat secondary hyperparathyroidism (SHPT) in patients with stage 3-4 chronic kidney disease (CKD) and vitamin D insufficiency
- Reduces plasma iPTH and increases serum 25D, with safety profile similar to placebo
- Minimal adverse effects on serum calcium or phosphorus, key drivers of vascular calcification

Approved in US and Europe for treating secondary hyperparathyroidism in patients with stage 3-4 CKD patients

- RAYALDEE, after oral administration, gradually releases calcifediol, to safely and reliably raise a patient’s serum total 25-hydroxyvitamin D (25D) well above current targets of 20 or 30 ng/mL
- RAYALDEE is approved in the U.S. and many European countries for treating secondary hyperparathyroidism in non-dialysis CKD patients by raising 25D to levels as high as 100 ng/mL

** As reported by IQVIA

* 25-Hydroxyvitamin D₃ or Calcifediol
NGENLA™ (Somatrogon©) Long Acting Growth Hormone with Once a Week Injection Granted Regulatory Approvals in Major Markets, including Europe, Japan, Australia and Canada. Ongoing FDA review

- Received marketing approval in Japan for treatment of short stature due to growth hormone deficiency in January 2022
- Received Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency in February 2022
- Pfizer working with FDA to address any potential concerns and move toward approval, bring NGENLA to patients in the U.S. ASAP
OPKO Acquires ModeX Therapeutics in May 2022

Uniting the power of multiple medicines in a single molecule

Diseases are multi-faceted. We know medicines must be too. Our modular platforms unite the power of multiple biologics into single molecules to combat complex diseases.
A Transformational Step for OPKO and ModeX Therapeutics

- ModeX co-founded by Drs. Nabel and Zerhouni as a spin-off of the breakthrough lab led by Dr. Nabel at Sanofi since 2012
- Transformational technologies based on Multispecific antibodies and multivalent vaccine platforms
- Focused on Oncology, Infectious diseases, Vaccines and Immunology
- Track record of bringing multi-specifics to Clinic with 3 ongoing phase 1
- Strong IP foundation with 8 additional patents filed in 2022-22
- Brings to OPKO a world class team and expansion into novel biotherapeutics
- Portfolio eliciting strong interest from strategic partners
ModeX Leadership Team

Highly experienced team with deep research and technology expertise

Elias A. Zerhouni, M.D.
President and Vice Chairman of OPKO

Gary J. Nabel-CEO ModeX
Chief Innovation Officer of OPKO

Elizabeth Nabel
EVP Modex. CMO OPKO

Ji Zhang
Chief Operating Officer

Alexis Borisy
Board Member

John Mascola
Chief Scientific Officer

Ronnie Wei, Ph.D., M.B.A
Head of Biologics Discovery

Chih-Jen Wei
Head of Synthetic Biologics

Vijay Chhaklani
Chief Technology Officer

Zhi-yong Yang
Head of Research
Central concept: Synergistic targeting of disease drivers

**Biological Synergy and Multi-Targeting of disease drives efficacy**

- Deep understanding of validated molecular networks and pathways and unique combinations reduce biological risk
- Scientific evidence indicates most diseases will require a combination of therapies to achieve success
- Success in humans: chemotherapy, antibiotics, Immunotherapy (Dupixent), vaccines
- Molecules attacking multiple points in disease pathway may result in efficacy in several diseases or improved risk/benefit in single disease

**“Dream Molecules”**
One Drug, Multiple Targets, Diverse Diseases

- Disease 1
- Disease 2
- Disease 3

Multi-targeted Ab, Peptide or Drug

Disease Symptoms
The STAR Platform: Next Generation Wholly-Owned ModeX Technology
Synergistic Targeting of Antigens and Receptors

1. Simplifies number of genes and eliminates mispairing that reduces yield.
2. Expression of up to 6 specificities with one or two mRNAs vectors, enabling gene delivery.
3. Gene delivery can accelerate clinical development by simplifying drug administration.
4. 8 provisional patents filed to date
ModeX Pipeline and Expansion Opportunities

ModeX has a robust early-stage pipeline with assets in key areas of the antibody market, and many potential applications that create exciting future expansion opportunities.

<table>
<thead>
<tr>
<th>Application</th>
<th>Opportunity</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>IND Enabling</th>
<th>Phase 1</th>
<th>Human PoC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established Commercial Indications²</td>
<td>HIV¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novel Viruses / Variants²</td>
<td>COVID¹, variants¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccines</td>
<td>EBV¹, Flu, Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solid Tumors³ (1st Gen TASER)</td>
<td>TNBC, Prostate, lung, pancreas, gastric</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solid Tumors³ (2nd Gen Stealth TASER)</td>
<td>TNBC, Prostate, lung, Pancreas, ovarian</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid Tumors⁴</td>
<td>Unspecified Leukemia / Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T cell Rejuvenation</td>
<td>Immune deficiency Car-T cells applications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

KEY:
CONCLUSIONS: 2023 and Beyond

• 2022 achieved necessary transitions and transformations: A strong basis for growth in 2023 and beyond
• Ongoing and upcoming product launches of RAYALDEE and NGENLA
• Portfolio development of ModeX supported by potential strategic partnerships with large pharmas and government agencies. R&D day Q1 2023
• Three programs (2 in oncology) in pre-IND stage anticipated to reach clinic in early 2024
• Continued performance of Latin America and Europe pharmaceutical division
• Bioreference Health resuming growth post COVID in 2023